Gofen & Glossberg LLC IL bought a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 2,060 shares of the biopharmaceutical company’s stock, valued at approximately $356,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Flagship Harbor Advisors LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at about $109,000. Envestnet Asset Management Inc. acquired a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at about $119,000. WealthTrust Fairport LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at about $104,000. Cowen Prime Services LLC grew its stake in shares of GW Pharmaceuticals PLC- by 708.0% in the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 885 shares during the period. Finally, BNP Paribas Arbitrage SA grew its stake in shares of GW Pharmaceuticals PLC- by 497.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 999 shares during the period. Institutional investors own 75.44% of the company’s stock.
Several analysts have recently commented on GWPH shares. Bank of America raised their target price on GW Pharmaceuticals PLC- from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, June 26th. Stifel Nicolaus started coverage on GW Pharmaceuticals PLC- in a research note on Tuesday, August 14th. They issued a “buy” rating and a $181.00 target price for the company. Morgan Stanley raised their target price on GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Finally, BidaskClub downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $185.00.
GWPH stock opened at $143.32 on Friday. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of -20.62 and a beta of 2.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21. GW Pharmaceuticals PLC- has a 52-week low of $101.07 and a 52-week high of $179.65.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.14. The business had revenue of $3.46 million during the quarter, compared to the consensus estimate of $2.00 million. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. On average, analysts forecast that GW Pharmaceuticals PLC- will post -9.11 EPS for the current year.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Read More: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.